Nuvation Bio
NUVB • NYSE
Nuvation Bio is a biotechnology company in the healthcare sector trading on NYSE, led by CEO David T. Hung, with a market cap of $1.5B.
CEODavid T. Hung
Next Earnings
Upcoming earnings announcement for Nuvation Bio
Date
Wednesday, May 6, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.55
Revenue Estimate
$65.4M
Earnings History
Past 12 earnings reports for Nuvation Bio
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | Q4 2025 | -$0.11Est: -$0.07 | -57.1% | $41.9MEst: $33.5M | +25.1% |  10-K |
| Nov 3, 2025 | Q3 2025 | -$0.16Est: -$0.16 | 0.0% | $13.1MEst: $6.8M | +92.9% | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.17Est: -$0.15 | -13.3% | $4.8MEst: $1.3M | +286.6% | 10-Q |
| May 7, 2025 | Q1 2025 | -$0.16Est: -$0.12 | -33.3% | $3.1MEst: $416.7K | +640.2% | 10-Q |
| Mar 6, 2025 | Q4 2024 | -$0.15Est: -$0.14 | -7.1% | $5.7M | — | 10-K |
| Nov 6, 2024 | Q3 2024 | -$0.15Est: -$0.14 | -7.1% | $727.0K | — | 10-Q |
| Aug 5, 2024 | Q2 2024 | -$0.15Est: -$0.06 | -150.0% | $1.4M | — | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.07Est: -$0.10 | +30.0% | - | — | 10-Q |
| Feb 29, 2024 | Q4 2023 | -$0.06Est: -$0.10 | +40.0% | - | — | 10-K/A |
| Nov 2, 2023 | Q3 2023 | -$0.09Est: -$0.11 | +18.2% | - | — | — |
| Aug 3, 2023 | Q2 2023 | -$0.09Est: -$0.11 | +18.2% | - | — | — |
| May 4, 2023 | Q1 2023 | -$0.10Est: -$0.10 | 0.0% | - | — | — |